Three‐year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin
- 24 April 2006
- journal article
- research article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 22 (6), 477-482
- https://doi.org/10.1002/dmrr.642
Abstract
Background Several studies have shown an increase of mortality in diabetic patients treated with combinations of sulphonylureas and biguanides. Comparisons between different insulin secretagogues in combination with metformin with respect to all‐cause mortality have not been reported so far. Methods An observational cohort study was performed on a consecutive series of 2002 outpatients with type 2 diabetes mellitus. Of these patients, 696 (34.8%) were receiving combinations of insulin secretagogues and biguanides at enrolment. Three‐year mortality was assessed through research in the City of Florence Registry Office. Results During follow‐up, 295 deaths were recorded. Among patients on combined secretagogue and biguanide treatment, glibenclamide was associated with a significantly higher yearly mortality (8.7%) than repaglinide (3.1%; p = 0.002), gliclazide (2.1%; p = 0.001), and glimepiride (0.4%; p < 0.0001). After adjusting for potential confounders (including age; duration of diabetes; Body Mass Index (BMI); lipid profile; HbA1c; insulin treatment; metformin doses; Charlson co‐morbidity score; CCS), mortality remained significantly higher in patients treated with combinations of glibenclamide and metformin when compared to those treated with different insulin secretagogues (OR with 95% CI: 2.09 [1.07;4.11]). Conclusions In the present study, sulphonylureas with greater selectivity for β‐cell receptors, such as glimepiride and gliclazide, were associated with a lower mortality when used in combination with metformin in comparison with glibenclamide. Safety of such combinations deserves further investigation. Copyright © 2006 John Wiley & Sons, Ltd.Keywords
This publication has 22 references indexed in Scilit:
- Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetesDiabetic Medicine, 2005
- Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort studyDiabetes/Metabolism Research and Reviews, 2004
- All‐cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanidesDiabetes/Metabolism Research and Reviews, 2003
- Oral antidiabetic treatment in patients with coronary disease: Time‐related increased mortality on combined glyburide/metformin therapy over a 7.7‐year follow‐upClinical Cardiology, 2001
- Effects of glibenclamide, a k atp channel blocker, on warm‐up phenomenon in type 11 diabetic patients with chronic stable angina pectorisClinical Cardiology, 2000
- Repaglinide – a new compound for the treatment of patients with type 2 diabetesThe Netherlands Journal of Medicine, 1999
- Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarctionAmerican Heart Journal, 1999
- 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of HypertensionClinical and Experimental Hypertension, 1999
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Validation of a combined comorbidity indexJournal of Clinical Epidemiology, 1994